.product_section .product_form, .product_gallery { opacity: 1; } .multi_select, form .select { display: block !important; } .image-element__wrap { display: none; }

May 28, 2026

CBG: What Is It and What Does the Research Show? | PureCraft CBD

Medical Disclaimer | This article is for informational and educational purposes only. CBG is a supplement, not a medication, and is not intended to diagnose, treat, cure, or prevent any disease. PureCraft CBD products are broad-spectrum zero-THC, batch-verified at purecraftcbd.com/pages/faq. Individual results may vary.

What Is CBG? The Precursor That Makes All Other Cannabinoids Possible

CBG — cannabigerol — is described as the 'mother cannabinoid,' and the description is biochemically accurate. In the young hemp plant, the first cannabinoid to form is cannabigerolic acid (CBGA). As the plant matures, enzymatic reactions convert CBGA into three main branches:CBDA (the precursor to CBD),THCA (the precursor to THC), andCBCA (the precursor to CBC). By harvest time, most of the CBGA has been consumed by these downstream conversions — which is why CBG typically represents less than 1% of the cannabinoid profile in mature hemp.

The scarcity of CBG in mature hemp makes it more expensive and technically challenging to produce in concentration than CBD — you need either young 'baby hemp' harvested before CBGA converts, or large volumes of mature material to extract meaningful quantities. This is why CBG was historically overlooked commercially despite its early pharmacological characterization.

The research picture changed significantly in the 2010s as extraction technology improved and the scientific community began characterizing CBG's distinct mechanisms — mechanisms that make it a genuinely different and complementary compound to CBD rather than a minor duplicate. The complete cannabinoid landscape, including how CBG fits alongside CBN, THCV, CBC, and terpenes, is covered inThe Complete Guide to CBD Cannabinoids: CBG, CBN, Delta-8, THCV, and More. This post focuses on CBG specifically.

CBG Mechanisms: How It Works — and How It Differs From CBD

α2-Adrenergic Receptor Agonism

The most pharmacologically distinctive aspect of CBG is its activation of α2-adrenergic receptors — a receptor system that neither CBD nor THC engages in a primary way. α2-adrenergic receptors regulate norepinephrine (noradrenaline) release throughout the sympathetic nervous system and in specific brain regions.

This α2-adrenergic mechanism is unique to CBG in the cannabinoid class and explains why CBG's pharmacological profile differs in important ways from CBD even where their anti-inflammatory and analgesic applications overlap.

5-HT1A Partial Antagonism — The Opposite of CBD

CBD is a5-HT1A agonist — it activates the serotonin receptor responsible for much of its anxiolytic effect. CBG is a5-HT1A partial antagonist — it blocks, rather than activates, the same receptor. This is one of the most mechanistically important distinctions between the two cannabinoids.

What does this mean in practice? At the trace concentrations present in broad-spectrum products, the pharmacological implications of CBG's 5-HT1A antagonism are unlikely to override CBD's 5-HT1A agonism. The two compounds coexist in a broad-spectrum formula without apparent functional conflict. But the distinction underscores that CBG and CBD are genuinely different pharmacological entities, not variations on the same theme — making the simplistic 'CBG is like a different version of CBD' framing inaccurate.

The serotonin system interaction also suggests that CBG's effects on mood and anxiety, if any, operate through a different mechanism than CBD's — potentially including the downstream dopaminergic and noradrenergic pathways that 5-HT1A antagonism modulates.

CB1 and CB2 Partial Agonism — Direct Receptor Binding

Unlike CBD — which modulates CB1 and CB2 indirectly through FAAH inhibition and allosteric effects — CBG hasdirect partial binding affinity for both CB1 and CB2 receptors. At the trace concentrations in most broad-spectrum products, this direct binding contributes an additive CB2 anti-inflammatory effect alongside CBD's indirect CB2 activation. Think of it as two different keys both turning the same lock — CBD turns it via the indirect FAAH pathway; CBG turns it more directly via partial receptor binding.

The CB1 partial agonism is pharmacologically relevant in the neuroprotection context — it contributes to the Huntington's disease model data discussed below — but at trace concentrations in broad-spectrum products does not produce psychoactive effects.

TRPV1 Modulation

CBG shares with CBD a modulatory effect on TRPV1 (transient receptor potential vanilloid 1) receptors — the pain and heat sensors concentrated in peripheral nerves, joint tissue, and the gut. This TRPV1 contribution adds to CBG's analgesic and anti-inflammatory profile, consistent with what would be expected from a cannabinoid with gut-specific anti-inflammatory activity.CBD for Inflammation: What the Science Actually Says covers TRPV1 in the CBD context; CBG's TRPV1 activity is consistent with that broader mechanism.

CBG Research: What Studies Actually Show

Inflammatory Bowel Disease — CBG's Strongest Research Area

The Borrelli et al. (2013) study published inBiochemical Pharmacology is CBG's most compelling piece of clinical research. In a murine model of colitis (experimental IBD induced by DNBS)

Critically, this study found CBG's gut anti-inflammatory effect to be comparable to or superior to CBD in the IBD-specific context, supporting the proposition that the two cannabinoids have complementary rather than identical anti-inflammatory applications — CBD being broader and more systemic, CBG being more gut-targeted.

This research does not mean CBG is a treatment for IBD — inflammatory bowel disease requires physician management. But it establishes a credible biological mechanism for gut-specific anti-inflammatory benefit that may be relevant for people with digestive discomfort or gut inflammation as part of a broader wellness protocol.CBD for Inflammation: What the Science Actually Says covers the complete anti-inflammatory framework.

Neuroprotection — Huntington's Disease Model

Valdeolivas et al. (2015) published a neuroprotection study inNeurotherapeutics evaluating CBG in the R6/2 mouse model of Huntington's disease — one of the standard preclinical models for this progressive neurodegenerative condition. The findings:

PPARγ activation is a mechanism that also appears in CBD's neuroprotective research, suggesting overlapping neuroprotective pathways between the two cannabinoids — potentially additive when combined in a broad-spectrum formula. This is preclinical-only evidence in a mouse model; human Huntington's disease trial data for CBG does not exist. But the mechanistic specificity of the finding gives it credibility as a genuine neuroprotective signal.

Antibacterial Activity — MRSA and Drug-Resistant Biofilms

Farha et al. (2020) published inACS Infectious Diseaseswhat may be CBG's most surprising research finding: in a systematic screening of cannabinoids for antibacterial activity,CBG was identified as the most potent antibacterial compound in the entire cannabinoid class — including CBD, CBN, THC, and CBC.

Against MRSA (methicillin-resistant Staphylococcus aureus) — one of the most clinically significant drug-resistant bacteria.

This antibacterial mechanism appears to operate through disruption of bacterial cell membranes — a different mechanism from conventional antibiotics, which reduces the likelihood of cross-resistance. The research team proposed CBG as a promising candidate for further antibiotic development.

This is not a claim that CBG oil treats bacterial infections. The Farha study was preclinical research identifying a mechanism and proving proof of concept — the path from this finding to a clinical antibiotic application is long and has not been traveled yet. But the antibacterial finding is one of the more pharmacologically specific and reproducible pieces of CBG research, and it distinguishes CBG from every other cannabinoid with high clarity.

Glaucoma — Intraocular Pressure Reduction

Earlier research, including Colasanti et al. (1984), established that cannabinoids reduce intraocular pressure in animal models — a finding relevant to glaucoma, where elevated IOP damages the optic nerve. CBG's α2-adrenergic agonism is the specific mechanism proposed for its IOP-reducing effects, distinguishing it from THC's IOP-reducing effect (which operates via CB1 receptor activation in the ciliary body).

The practical state of this research: there are no human CBG glaucoma trials. The animal model evidence is mechanistically credible but has not been translated into clinical evidence. Glaucoma requires physician management with established treatments (prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors) — CBG is not a replacement for any of these.

Appetite Stimulation

Brierley et al. (2016) found that low-dose CBG increased food intake in rats via a CB1-independent mechanism. This is worth noting because CBG's appetite effect is theopposite of THCV's (which suppresses appetite via CB1 antagonism) — a distinction relevant for different therapeutic applications. In the context of cancer cachexia, HIV-related wasting, or eating disorders involving restriction, appetite stimulation may be a clinically relevant goal. This remains preclinical and is not the primary reason most people consider CBG supplementation, but it is part of the pharmacological profile. SeeTHCV: What Is It and What Does the Research Show? for the appetite-suppressing counterpart.

CBG vs CBD: The Complete Side-by-Side Comparison

Factor	CBD	CBG	Clinical Notes
Primary receptor mechanism	5-HT1A agonism, CB2 indirect activation, TRPV1, FAAH inhibition	α2-adrenergic agonism, CB1/CB2 partial direct agonism, 5-HT1A partial antagonism	Opposite serotonergic directions: CBD activates 5-HT1A; CBG partially blocks it — distinct rather than redundant
Anti-inflammatory target	Systemic CB2 — joint synovium, peripheral immune tissue, skin	Gut-specific CB2 — colon tissue, IBD animal models, colonic macrophages	CBG has the stronger gut-specific anti-inflammatory mechanism; CBD is broader system-wide
Neuroprotection	BDNF via FAAH/anandamide; anti-neuroinflammation via CB2; antioxidant	Direct CB1/CB2 neuroprotection; PPARγ activation; Huntington's disease model evidence	Both neuroprotective but via distinct pathways — CBG has stronger direct receptor evidence
Antibacterial	Limited data	Strong — MRSA biofilm activity in Farha et al. (2020); most potent cannabinoid in screening	Unique to CBG in the cannabinoid class — no equivalent CBD antibacterial data
Eye health (IOP)	Limited data	Reduces intraocular pressure in animal models via α2-adrenergic mechanism	Preliminary — no human glaucoma trials; mechanism is credible via α2 receptor pathway
Appetite effect	Minimal direct effect	Stimulates appetite in animal models (unlike THCV which suppresses)	CBG and THCV have opposite appetite effects — clinically relevant for wasting vs obesity applications
Psychoactive?	No	No	Neither produces psychoactivity at any therapeutic dose
In PureCraft products?	Yes — primary ingredient	Yes — trace in broad-spectrum formula (verified on COA)	Broad-spectrum retains CBG; COA at purecraftcbd.com/pages/faq shows cannabinoid panel
Can you stack them?	Yes	Yes	Different mechanisms — no competition; stacking provides additive entourage benefit

The comparison table makes the core conclusion concrete:CBG and CBD are complementary, not competitive. They address inflammation through different tissue targets (CBG in the gut, CBD more systemically). They modulate 5-HT1A in opposite directions, suggesting potentially different mood effects. CBG has unique antibacterial and IOP mechanisms with no CBD equivalent. They are both non-psychoactive and both present in PureCraft's broad-spectrum formula — contributing additive entourage benefit through genuinely distinct pathways.

Does PureCraft's CBD Oil Contain CBG?

CBD Oil is a broad-spectrum hemp extract, which means it retains the natural cannabinoid profile of the hemp plant including trace CBG alongside CBD, CBN, CBC, and terpenes. The CBG concentration in a broad-spectrum product is trace — significantly lower than CBD — because mature hemp contains CBG in small amounts (typically under 1% of total cannabinoids).

This trace CBG is verified on PureCraft's batch-specificbatch-tested COA atpurecraftcbd.com/pages/faq. The cannabinoid panel on the COA shows CBD as the primary ingredient and lists the minor cannabinoids present, including CBG. This is one of the reasons COA review matters: it lets you verify that a 'broad-spectrum' label reflects actual minor cannabinoid presence rather than CBD isolate rebranded with broad-spectrum marketing language.

The entourage value of trace CBG inCBD Oil is not primarily in the CBG concentration itself — it is in the mechanistic contribution of CBG's distinct receptor interactions (α2-adrenergic, direct CB2 partial agonism) operating alongside CBD's mechanisms. SeeHow to Read a CBD Certificate of Analysis (COA): A Step-by-Step Guide for a step-by-step guide to reading the PureCraft COA andFull-Spectrum vs Broad-Spectrum vs CBD Isolate: The Complete Guide for the full comparison of broad-spectrum vs isolate.

Frequently Asked Questions

What is CBG?

CBG (cannabigerol) is a minor cannabinoid found in trace concentrations in mature hemp. It is the biosynthetic precursor from which CBD, THC, and CBC are derived — hence the 'mother cannabinoid' name. CBG works through α2-adrenergic receptors (unique in the cannabinoid class), has partial direct binding affinity for CB1 and CB2 receptors, and modulates TRPV1 channels. Research has demonstrated gut-specific anti-inflammatory effects, neuroprotection in Huntington's disease models, potent antibacterial activity against MRSA, and potential IOP reduction for glaucoma. It is non-psychoactive at any therapeutic dose.CBD Oil's broad-spectrum formula contains trace CBG verified on the batch-specificbatch-tested COA.

What are the benefits of CBG?

The most evidence-supported CBG applications are: gut anti-inflammatory effects (CBG's strongest research area via CB2 in colonic tissue — Borrelli et al., 2013), neuroprotection in Huntington's disease preclinical models (Valdeolivas et al., 2015), antibacterial activity against MRSA drug-resistant biofilms (Farha et al., 2020), and potential intraocular pressure reduction relevant to glaucoma. CBG also contributes to the entourage effect in broad-spectrum formulas alongside CBD, CBN, CBC, and hemp terpenes. All research is preclinical or early-stage — CBG is not a treatment for IBD, Huntington's disease, MRSA infections, or glaucoma.

Is CBG better than CBD?

Neither is 'better' — they address different biological targets through different mechanisms. CBD has the broader evidence base and the stronger anxiety, sleep, and systemic anti-inflammatory applications. CBG has the stronger gut-specific anti-inflammatory, antibacterial, and neuroprotective direct receptor mechanisms. The most accurate framing: they are complementary, not competitive. This is exactly why PureCraft retains trace CBG inCBD Oil's broad-spectrum formula — not to replace CBD's mechanisms but to add CBG's distinct contributions to the formula's overall effect profile.

Does CBG get you high?

No. CBG is non-psychoactive at any therapeutic dose. It does not activate CB1 receptors with sufficient potency to produce intoxication. CBG's CB1 binding affinity is low, and the concentrations present in broad-spectrum CBD products are trace — far too small to produce psychoactive effects even if the receptor potency were sufficient. CBG is not scheduled as a controlled substance and has no known abuse potential.

What is CBG good for?

Based on current research, CBG is most likely to contribute benefit in: gut inflammation and digestive discomfort (CB2 colonic mechanism), neuroprotective contexts where broad-spectrum cannabinoid support is being used (CB1/CB2 and PPARγ), and as an entourage effect contributor in broad-spectrum formulas that amplifies CBD's effects. The antibacterial MRSA research is genuinely interesting but requires significant further development before clinical applications can be discussed. InCBD Oil, CBG is one of several minor cannabinoids contributing to the complete entourage profile alongside CBN, CBC, and terpenes.

Does CBD oil contain CBG?

Broad-spectrum CBD oil (likeCBD Oil) retains trace CBG from the hemp plant. CBD isolate products do not — they contain only purified CBD with everything else filtered out. Products labeled 'broad-spectrum' should verify CBG presence on their COA cannabinoid panel; a COA showing only CBD without any minor cannabinoids suggests the product may be isolate-based despite broad-spectrum labeling. PureCraft'sbatch-tested COA is publicly accessible atpurecraftcbd.com/pages/faq and shows the full cannabinoid panel including CBG.

Is CBG legal?

Yes. CBG derived from hemp (cannabis with less than 0.3% delta-9 THC) is federally legal in the United States under the 2018 Farm Bill. CBG is not scheduled as a controlled substance and has no psychoactive properties that would prompt scheduling. It is regulated as a hemp-derived cannabinoid supplement in the same legal category as CBD. International legal status varies by country, but CBG is broadly considered legal in most jurisdictions where hemp CBD is legal.

How does CBG work in the body?

CBG works through four primary mechanisms:(1) α2-adrenergic receptor agonism — activating receptors that regulate norepinephrine, intraocular pressure, and cardiovascular sympathetic tone;(2) CB1 and CB2 partial direct agonism — turning on cannabinoid receptors with lower potency than THC but more directly than CBD;(3) 5-HT1A partial antagonism — modulating the serotonin receptor in the opposite direction from CBD's 5-HT1A agonism;(4) TRPV1 modulation — influencing pain and heat sensors in peripheral tissue. Together these mechanisms contribute gut anti-inflammatory effects, neuroprotective activity, potential IOP reduction, and antibacterial properties unique in the cannabinoid class. SeeWhat Is the Endocannabinoid System? A Complete Guide for the foundational ECS framework andThe Complete Guide to CBD Cannabinoids: CBG, CBN, Delta-8, THCV, and More for how CBG fits in the complete cannabinoid guide.

The Bottom Line: CBG's Place in the Cannabinoid Landscape

CBG is not simply 'another minor cannabinoid.' It is a pharmacologically distinct compound with a receptor mechanism profile — particularly the α2-adrenergic agonism, direct CB1/CB2 partial binding, and 5-HT1A antagonism — that genuinely differs from CBD in important ways. Its research portfolio includes some of the most mechanistically specific cannabinoid findings: the Borrelli IBD study, the Valdeolivas Huntington's neuroprotection study, and the Farha MRSA antibacterial screening represent genuine scientific advances, not wellness marketing.

In practical terms, the trace CBG inCBD Oil's broad-spectrum formula contributes to the formula's anti-inflammatory breadth, neuroprotective profile, and entourage effect — mechanisms that CBD isolate products at the same milligram dose cannot replicate. For the most complete cannabinoid context, return toThe Complete Guide to CBD Cannabinoids: CBG, CBN, Delta-8, THCV, and More. For the other minor cannabinoids:CBN for Sleep: The Science Behind the Sleepy Cannabinoid |THCV: What Is It and What Does the Research Show? |CBC: The Inflammation and Mood Cannabinoid Explained.

PureCraft CBD Oil 1000mg — broad-spectrum, nano-optimized, 0.00% THC, trace CBG and CBC and CBN retained.batch-tested COA.browse all PureCraft CBD products.

Medical Disclaimer| This article is for informational and educational purposes only. CBG is a supplement, not a medication. CBG is not a treatment for IBD, Huntington's disease, MRSA, glaucoma, or any other medical condition. Consult a qualified healthcare provider before beginning any supplement regimen. PureCraft CBD products are not intended to diagnose, treat, cure, or prevent any disease.